{"id":"combination-with-dopamine-agonist-cabergoline","safety":{"commonSideEffects":[{"rate":"27","effect":"Nausea"},{"rate":"24","effect":"Headache"},{"rate":"14","effect":"Dizziness"},{"rate":"12","effect":"Fatigue"},{"rate":"7","effect":"Postural hypotension"},{"rate":null,"effect":"Valvular heart disease (rare, long-term use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabergoline binds to dopamine D2 receptors on lactotroph cells in the pituitary, mimicking dopamine's natural inhibitory effect on prolactin release. This leads to sustained suppression of elevated prolactin levels. The drug is long-acting due to its high receptor affinity and slow clearance, allowing for less frequent dosing compared to other dopamine agonists.","oneSentence":"Cabergoline is a dopamine agonist that stimulates dopamine D2 receptors to inhibit prolactin secretion from the anterior pituitary gland.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:04.726Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperprolactinemia (prolactin-secreting pituitary adenomas)"},{"name":"Idiopathic hyperprolactinemia"},{"name":"Restless legs syndrome (RLS)"}]},"trialDetails":[{"nctId":"NCT01278342","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Acromegaly","enrollment":70},{"nctId":"NCT01014793","phase":"","title":"Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2005-05","conditions":"Acromegaly","enrollment":19},{"nctId":"NCT00595140","phase":"PHASE4","title":"Acute Application of Pegvisomant and Octreotide in Acromegaly","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2008-01","conditions":"Acromegaly","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cabergoline: Dostinex 0.5mg: MA number 32411.00.00"],"phase":"marketed","status":"active","brandName":"combination with dopamine agonist cabergoline","genericName":"combination with dopamine agonist cabergoline","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabergoline is a dopamine agonist that stimulates dopamine D2 receptors to inhibit prolactin secretion from the anterior pituitary gland. Used for Hyperprolactinemia (prolactin-secreting pituitary adenomas), Idiopathic hyperprolactinemia, Restless legs syndrome (RLS).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}